Investigation of the effect of recombinant human soluble thrombomodulin on the improvement of renal injury and mortality in septic patients with disseminated intravascular coagulation

Investigation of the effect of recombinant human soluble thrombomodulin on the improvement of renal injury and mortality in septic patients with disseminated intravascular coagulation - Investigation of the effect of recombinant human soluble thrombomodulin on the improvement of renal injury and mortality in septic patients with disseminated intravascular coagulation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037245

Enrollment

200

Registered

2019-07-03

Start date

2019-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septic DIC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: septic DIC

Exclusion criteria

Exclusion criteria: the patients with chronic kidney disease on hemodialysis the patients who are under 18 years old

Design outcomes

Primary

Measure	Time frame
the dependence of renal replacement therapy after ICU discharge	—

Secondary

Measure	Time frame
the number of renal replacement therapy during ICU stay: the length of renal replacement therapy during ICU stay; the number of days free of continuous renal replacement therapy (CRRT free-days), serum creatinine level at ICU admission, ICU discharge, and hospital discharge, death at 28 days, 90 days, and 180 days	—

Countries

Japan

Contacts

Public ContactMasayuki Akatsuka

Sapporo Medical University, School of Medicine Department of Anesthesiology

maasa_aka@icloud.com011-611-2111

Outcome results